Compositions and methods for modulating apolipoprotein (a) expression
First Claim
1. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 20 contiguous nucleobases complementary to an equal length portion of nucleobases 3901 to 3920 of SEQ ID NO:
- 1, wherein the nucleobase sequence of the modified oligonucleotide is at least 80% complementary to SEQ ID NO;
1; and
wherein the conjugate group comprises;
1 Assignment
0 Petitions
Accused Products
Abstract
Provided herein are oligomeric compounds with conjugate groups targeting apoplipoprotein (a) [apo(a)]. In certain embodiments, the apo(a) targeting oligomeric compounds are conjugated to N-Acetylgalactosamine. Also disclosed herein are conjugated oligomeric compounds targeting apo(a) for use in decreasing apo(a) to treat, prevent, or ameliorate diseases, disorders or conditions related to apo(a) and/or Lp(a). Certain diseases, disorders or conditions related to apo(a) and/or Lp(a) include inflammatory, cardiovascular and/or metabolic diseases, disorders or conditions. The conjugated oligomeric compounds disclosed herein can be used to treat such diseases, disorders or conditions in an individual in need thereof.
-
Citations
26 Claims
-
1. A compound comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 20 contiguous nucleobases complementary to an equal length portion of nucleobases 3901 to 3920 of SEQ ID NO:
- 1, wherein the nucleobase sequence of the modified oligonucleotide is at least 80% complementary to SEQ ID NO;
1; and
wherein the conjugate group comprises;
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
- 1, wherein the nucleobase sequence of the modified oligonucleotide is at least 80% complementary to SEQ ID NO;
Specification